Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The hepatitis B infection treatment market was valued at USD 4.16 Billion in 2025, driven by the rising cases of hepatitis infections and better diagnostic procedures across the 8 major markets. The market is anticipated to grow at a CAGR of 4.60% during the forecast period of 2026-2035 to achieve a value of USD 6.52 Billion by 2035. The market growth is driven by rising adoption of digital platforms, telemedicine, and point-of-care diagnostic tools to improve screening, linkage to care, and monitoring, particularly in underserved or rural populations.
Key Market Trends Insights
- The rising diagnosis rates and global vaccination drives will continue to support steady market expansion over the coming decade.
- Emerging oral antivirals with improved safety profiles will likely shift treatment preferences and boost long-term adherence.
- Many regions, especially in Asia and Africa, are witnessing increased availability of cost-effective generics, driving treatment access and fueling market demand.
Market Size & Forecast
- Market Size in 2025: USD 4.16 Billion
- Projected Market Size in 2035: USD 6.52 Billion
- CAGR from 2026 to 2035: 4.60%
Compound Annual Growth Rate
4.6%
Value in USD Billion
2026-2035
Hepatitis B Infection Treatment Market Overview
Hepatitis B infection treatment focuses on suppressing the virus and preventing liver damage. According to the World Health Organization’s 2024 Global Hepatitis Report, hepatitis B diagnosis rates increased from 10% in 2019 to 13% in 2024, while treatment coverage rose from just 2% to 3% globally. Regionally, the WHO African Region bears the highest burden, accounting for 63% of new hepatitis B infections. However, only 18% of newborns receive the birth-dose vaccination, a critical intervention to prevent early transmission. In the Western Pacific Region (which accounts for 47% of global hepatitis B deaths) treatment coverage is only 23% among those diagnosed, far below levels needed to significantly reduce mortality. Current options include antiviral drugs like tenofovir and entecavir, immunomodulators, and supportive therapies. While no complete cure exists, long-term treatment can manage chronic cases effectively. Vaccination plays a vital role in prevention. Advancements in drug development, rising awareness, and government initiatives are expanding access to care.
Hepatitis B Infection Treatment Market Growth Drivers
Adoption of Gene-Editing Therapies to Boost Market Growth
Increasing demand for curative therapies and growing investment in gene-editing technologies are driving innovation in the landscape. For instance, in March 2025, Precision BioSciences announced that the U.S. FDA cleared its Investigational New Drug (IND) application for PBGENE-HBV, a meganuclease-edited in vivo therapeutic developed using its proprietary ARCUS® platform. The clearance enables expansion of the ELIMINATE-B trial into the U.S., marking the first investigational in vivo gene-editing therapy approved to enter a clinical trial for chronic hepatitis B in the country. This breakthrough positions gene-editing-based therapies as a promising frontier in the forecast period, likely shifting the market toward potentially curative treatments and attracting significant clinical and commercial interest.
Hepatitis B Infection Treatment Market Trends
GSK received approval from Japan’s Ministry of Health, Labour and Welfare in August 2026 for Hibsago, the brand name for bepirovirsen, as a functional cure treatment for chronic hepatitis B in eligible adults. The antisense oligonucleotide is indicated for patients who have received at least six months of prior nucleos(t)ide analogue therapy and meet specified viral markers. The approval represents the first global regulatory approval for bepirovirsen and introduces a finite-duration treatment approach aimed at functional cure rather than continuous viral suppression.
Precision BioSciences reported new clinical evidence from its Phase 1 ELIMINATE-B trial of PBGENE-HBV in August 2026. Liver biopsy data showed a 1-log reduction in cccDNA-derived transcripts after treatment, with less than 1% of cccDNA remaining in one evaluated patient. The company also reported sustained loss of HBV pre-genomic RNA in all evaluable patients who had detectable levels at baseline. PBGENE-HBV is being developed as an in vivo gene-editing treatment designed to directly target cccDNA, a persistent viral reservoir in chronic hepatitis B.
nChroma Bio received authorisation in December 2025 to initiate a Phase 1/2 clinical trial of CRMA-1001 for chronic hepatitis B. The company’s epigenetic silencer is designed to suppress HBV viral activity by targeting genetic mechanisms associated with persistent infection. The authorisation marked the transition of CRMA-1001 into clinical development, with first patient dosing planned for early 2026. Preclinical studies reported durable reductions in HBV antigens and HBV DNA across multiple experimental models. The programme reflects increasing investment in genetic medicines designed to achieve longer-lasting viral control.
The European TherVacB project began a clinical trial in July 2025 to evaluate a therapeutic vaccination strategy for chronic hepatitis B. Coordinated by Helmholtz Munich, the programme is developing an immunotherapeutic approach designed to stimulate stronger HBV-specific immune responses and potentially provide a curative treatment option. The trial followed more than a decade of preclinical and translational research and incorporates a European HBV Patient Registry to support patient recruitment and research activities. The development highlights growing interest in therapeutic vaccines and immune-based approaches alongside conventional long-term antiviral treatment.
Shift From Viral Suppression Toward Functional Cure
The hepatitis B treatment landscape is increasingly moving beyond long-term viral suppression toward functional cure as the principal therapeutic objective. Conventional nucleos(t)ide analogues can effectively suppress HBV replication but rarely eliminate hepatitis B surface antigen. Newer therapies are therefore being developed to achieve sustained HBsAg loss and undetectable HBV DNA after treatment ends. GSK’s bepirovirsen recorded a 19% functional cure rate in the overall B-Well Phase III population and 26% among patients with lower baseline HBsAg levels. These developments are strengthening industry focus on finite-duration treatments that could reduce dependence on lifelong antiviral therapy.
Increasing Development of RNA-Targeting Therapies
RNA-targeting technologies are becoming an important area of innovation in chronic hepatitis B treatment. Small interfering RNAs and antisense oligonucleotides are designed to reduce HBV transcripts and suppress production of viral proteins, particularly HBsAg. Bepirovirsen is an advanced example, while several siRNA candidates are being evaluated in clinical development. Recent research also highlights RNA destabilisers as another emerging approach. These therapies are increasingly being assessed as components of broader treatment strategies rather than standalone antiviral approaches. Their ability to substantially lower viral antigen levels could help restore immune control and improve the possibility of achieving a functional cure.
Growing Interest in Combination Treatment Regimens
Combination therapy is gaining importance as researchers seek to address several biological mechanisms responsible for persistent HBV infection. Emerging approaches combine conventional nucleos(t)ide analogues with antigen-lowering agents, immunotherapies or other direct-acting treatments. The objective is to suppress viral replication, reduce circulating antigens and simultaneously strengthen HBV-specific immune responses. Clinical research is examining combinations involving siRNAs, antisense oligonucleotides, therapeutic vaccines and pegylated interferon. A 2026 review identified rational combination regimens as an important direction for improving functional cure rates. This approach could also allow different therapies to be used sequentially, depending on individual treatment response.
Emergence of Gene and Epigenetic Editing Approaches
Gene editing and epigenetic technologies are creating new approaches for addressing covalently closed circular DNA, or cccDNA, which enables HBV to persist inside liver cells. Precision BioSciences reported clinical evidence in 2026 showing direct targeting of cccDNA with its PBGENE-HBV gene-editing therapy. Separately, nChroma Bio’s CRMA-1001 uses epigenetic editing to silence HBV genetic material without making conventional DNA cuts. These approaches differ from standard antiviral medicines because they aim to act on persistent viral genetic reservoirs rather than only suppress viral replication. Their development reflects increasing interest in treatments that could produce deeper and more durable viral control.
Greater Use of Biomarkers for Treatment Personalisation
Treatment development is increasingly incorporating biomarkers beyond conventional HBV DNA measurements to identify patients most likely to respond and assess whether treatment is moving toward functional cure. Quantitative HBsAg is receiving particular attention because it provides information about viral antigen production and can help evaluate treatment response. HBV core-related antigen, or HBcrAg, is also being investigated as a complementary indicator of viral activity and cccDNA transcription. Emerging research suggests that monitoring multiple biomarkers can help assess relapse risk and guide treatment strategies. This is supporting a more personalised approach in which baseline antigen levels and treatment response influence therapeutic selection and sequencing.
Hepatitis B Infection Treatment Market Segmentation
Hepatitis B Infection Treatment Market Report and Forecast 2026-2035 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Acute
- Chronic
Market Breakup by Treatment Type
- Immunomodulator Drugs
- Vaccines
- Antiviral Drugs
- Surgery
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Others
Market Breakup by Region
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Hepatitis B Infection Treatment Market Share
Chronic Type to Dominate the Share by Type
Chronic hepatitis B infection is poised to hold the largest market share by type due to its long-term nature and global prevalence, especially in regions like Asia and sub-Saharan Africa. The increasing burden of chronic cases requires ongoing treatment and monitoring, fuelling consistent demand for therapeutic drugs and diagnostics. With growing awareness and improved diagnosis rates, this segment is expected to drive market expansion through the forecast period, supported by government-led screening and vaccination programs.
Antiviral Drugs to Hold a Substantial Hepatitis B Infection Treatment Market Value for Segmentation by Treatment Type
Antiviral drugs will likely dominate the treatment type segment, driven by their effectiveness in suppressing hepatitis B virus replication and preventing disease progression. As per the analysis by Expert Market Research, the global antiviral drugs market is anticipated to grow at a CAGR of 4.10% during the forecast period of 2025-2034. These drugs, especially tenofovir and entecavir, are widely prescribed due to their safety profiles and long-term efficacy. With rising treatment accessibility and strong pipeline development, this segment will continue to grow. Increased funding for drug development and broader adoption in high-burden regions are key factors sustaining its leadership in the global market.
Oral Route to Dominate the Share by Route of Administration
The oral route is expected to hold the largest market share by route of administration, primarily due to patient preference, ease of use, and better compliance. Most antiviral hepatitis B treatments are available in oral formulations, which facilitate long-term therapy for chronic cases. The convenience of self-administration at home reduces hospital dependency, supporting broader access. Future market growth will be reinforced by the development of novel oral formulations with improved bioavailability and safety profiles.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Hepatitis B Infection Treatment Market Analysis by Region
The United States is expected to lead the market, driven by high awareness, advanced diagnostics, and strong pharmaceutical presence. Major players like Gilead and GlaxoSmithKline dominate with antivirals such as tenofovir and entecavir. Widespread screening programs, immigration from endemic regions, and robust insurance coverage support market growth. In Europe, Germany has a structured healthcare system and offers full reimbursement for hepatitis B therapies. The country emphasizes early diagnosis and consistent long-term management using antivirals. Public awareness and screening efforts are strong, and the presence of multinational pharmaceutical companies ensures access to the latest treatments.
Leading Players in the Hepatitis B Infection Treatment Market
The key features of the market report comprise clinical trials and pipeline analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Accord Healthcare (Intas Pharmaceuticals Ltd.)
Headquartered in the United Kingdom and operating as a subsidiary of Intas Pharmaceuticals (founded in 1984 in India), Accord Healthcare offers a wide range of affordable generic medicines, including treatments for hepatitis B. The company is known for its strong presence in oncology, cardiology, and infectious diseases. Its extensive manufacturing and R&D capabilities enable the timely development of antiviral drugs. Accord’s global distribution and compliance with international regulatory standards strengthen its role in hepatitis B infection management.
Apotex Inc. (SK Capital Partners)
Founded in 1974 and based in Toronto, Canada, Apotex Inc. is a prominent pharmaceutical company now under the ownership of SK Capital Partners. It is known for producing high-quality generic medications across various therapeutic areas, including hepatitis B. Apotex offers cost-effective antiviral drugs and actively supplies healthcare systems globally. Its research-driven approach, coupled with consistent regulatory approvals, supports the development of reliable treatment options in the hepatitis B infection treatment landscape.
Aurobindo Pharma
Established in 1986 and headquartered in Hyderabad, India, Aurobindo Pharma is a leading global pharmaceutical manufacturer with a strong presence in antiviral and infectious disease segments. The company’s hepatitis B portfolio includes key antiviral medications like tenofovir and lamivudine. Aurobindo’s vertically integrated business model, global regulatory compliance, and robust R&D infrastructure position it as a vital player in the hepatitis B treatment market, catering to both developed and emerging regions.
Bristol-Myers Squibb Company
Founded in 1887 and headquartered in New York, USA, Bristol-Myers Squibb is a major biopharmaceutical company known for pioneering innovation in immunology, oncology, and virology. In the hepatitis B market, it is best known for Baraclude (entecavir), a leading antiviral therapy. BMS invests heavily in clinical research and strategic collaborations to advance its treatment offerings. With a focus on precision medicine and patient-centered care, the company remains a key contributor to hepatitis B treatment globally.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Gilead Sciences, Inc., GSK plc, Lupin, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Zydus Healthcare Limited.
Key Questions Answered in the Hepatitis B Infection Treatment Market
- What was the hepatitis B infection treatment market value in 2025?
- What is the hepatitis B infection treatment market forecast outlook for 2026-2035?
- What are the major factors aiding the hepatitis B infection treatment demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major hepatitis B infection treatment market trends?
- Which type will lead the market segment?
- Which treatment type will lead the market segment?
- Which route of administration will lead the market segment?
- Which end user will lead the market segment?
- Who are the key players involved in the hepatitis B infection treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$3299 $2969
-
$5499 $4949
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
